Citigroup Issues Positive Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its price objective boosted by Citigroup from $16.00 to $22.00 in a research note issued to investors on Tuesday, Benzinga reports. Citigroup currently has a sell rating on the life sciences company’s stock.

Other analysts have also issued reports about the stock. Bank of America dropped their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. JMP Securities dropped their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a report on Tuesday, July 30th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Finally, Morgan Stanley lifted their target price on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.25.

Integra LifeSciences Trading Up 3.3 %

Integra LifeSciences stock opened at $24.91 on Tuesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The firm has a 50-day moving average of $18.68 and a 200-day moving average of $24.41. The company has a market cap of $1.93 billion, a price-to-earnings ratio of 85.90, a P/E/G ratio of 0.66 and a beta of 1.08. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. The firm had revenue of $380.80 million during the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The business’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.76 earnings per share. On average, equities analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of large investors have recently made changes to their positions in IART. Blue Trust Inc. grew its holdings in Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares in the last quarter. CWM LLC boosted its position in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Integra LifeSciences in the second quarter valued at about $114,000. Northwest Investment Counselors LLC bought a new position in Integra LifeSciences during the third quarter worth about $73,000. Finally, EntryPoint Capital LLC raised its stake in Integra LifeSciences by 191.0% in the 1st quarter. EntryPoint Capital LLC now owns 4,580 shares of the life sciences company’s stock worth $162,000 after purchasing an additional 3,006 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.